Alvotech's (ALVO) Q4 approval and launch timelines remain intact, with upcoming approval and launch catalysts providing potential upside, UBS said in a note.

The brokerage said the stock reacted positively, despite the Q2 results being relatively in-line, on the back of the timelines.

UBS said it remains confident in FDA approval following the recent inspection closure and assigned Q4 FDA goal date. For AVT05, management remains confident in a Q4 launch despite ongoing litigation with Johnson & Johnson, UBS said.

For AVT16, management continues to express confidence in a near-term US launch opportunity, as well as in securing a favorable IP outcome and FDA approval, UBS said.

UBS maintained buy rating and $6 price target.

Price: 5.35, Change: +0.92, Percent Change: +20.65